519 related articles for article (PubMed ID: 29289556)
1. Chronopathophysiological implications of orexin in sleep disturbances and lifestyle-related disorders.
Tsuneki H; Wada T; Sasaoka T
Pharmacol Ther; 2018 Jun; 186():25-44. PubMed ID: 29289556
[TBL] [Abstract][Full Text] [Related]
2. Timed Inhibition of Orexin System by Suvorexant Improved Sleep and Glucose Metabolism in Type 2 Diabetic db/db Mice.
Tsuneki H; Kon K; Ito H; Yamazaki M; Takahara S; Toyooka N; Ishii Y; Sasahara M; Wada T; Yanagisawa M; Sakurai T; Sasaoka T
Endocrinology; 2016 Nov; 157(11):4146-4157. PubMed ID: 27631554
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the role of orexins in the pathophysiology and treatment of depression: A comprehensive review.
Shariq AS; Rosenblat JD; Alageel A; Mansur RB; Rong C; Ho RC; Ragguett RM; Pan Z; Brietzke E; McIntyre RS
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jun; 92():1-7. PubMed ID: 30576764
[TBL] [Abstract][Full Text] [Related]
4. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.
Coleman PJ; Gotter AL; Herring WJ; Winrow CJ; Renger JJ
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():509-533. PubMed ID: 27860547
[TBL] [Abstract][Full Text] [Related]
5. Toward the Mysteries of Sleep.
Yanagisawa M
Keio J Med; 2019; 68(1):27. PubMed ID: 30905886
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of action of suvorexant.
Stahl SM
CNS Spectr; 2016 Jun; 21(3):215-8. PubMed ID: 27322687
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of SAMP8 Mice as a Model for Sleep-Wake and Rhythm Disturbances Associated with Alzheimer's Disease: Impact of Treatment with the Dual Orexin (Hypocretin) Receptor Antagonist Lemborexant.
Beuckmann CT; Suzuki H; Musiek ES; Ueno T; Sato T; Bando M; Osada Y; Moline M
J Alzheimers Dis; 2021; 81(3):1151-1167. PubMed ID: 33843668
[TBL] [Abstract][Full Text] [Related]
8. Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia.
Owen RT
Drugs Today (Barc); 2016 Jan; 52(1):29-40. PubMed ID: 26937493
[TBL] [Abstract][Full Text] [Related]
9. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
Hoyer D; Jacobson LH
Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
[TBL] [Abstract][Full Text] [Related]
10. Suvorexant to treat alcohol use disorder and comorbid insomnia: Plan for a phase II trial.
Campbell EJ; Norman A; Bonomo Y; Lawrence AJ
Brain Res; 2020 Feb; 1728():146597. PubMed ID: 31837287
[TBL] [Abstract][Full Text] [Related]
11. Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders. Rationale for development and current status.
Mieda M; Sakurai T
CNS Drugs; 2013 Feb; 27(2):83-90. PubMed ID: 23359095
[TBL] [Abstract][Full Text] [Related]
12. Suvorexant: first global approval.
Yang LP
Drugs; 2014 Oct; 74(15):1817-22. PubMed ID: 25227290
[TBL] [Abstract][Full Text] [Related]
13. Insight Into Reduction of Wakefulness by Suvorexant in Patients With Insomnia: Analysis of Wake Bouts.
Svetnik V; Snyder ES; Tao P; Scammell TE; Roth T; Lines C; Herring WJ
Sleep; 2018 Jan; 41(1):. PubMed ID: 29112763
[TBL] [Abstract][Full Text] [Related]
14. Neurophysiological and Behavioral Effects of Anti-Orexinergic Treatments in a Mouse Model of Huntington's Disease.
Cabanas M; Pistono C; Puygrenier L; Rakesh D; Jeantet Y; Garret M; Cho YH
Neurotherapeutics; 2019 Jul; 16(3):784-796. PubMed ID: 30915710
[TBL] [Abstract][Full Text] [Related]
15. Repurposing the dual orexin receptor antagonist suvorexant for the treatment of opioid use disorder: why sleep on this any longer?
James MH; Fragale JE; Aurora RN; Cooperman NA; Langleben DD; Aston-Jones G
Neuropsychopharmacology; 2020 Apr; 45(5):717-719. PubMed ID: 31986520
[No Abstract] [Full Text] [Related]
16. Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease.
Sun H; Palcza J; Rosenberg R; Kryger M; Siringhaus T; Rowe J; Lines C; Wagner JA; Troyer MD
Respir Med; 2015 Mar; 109(3):416-26. PubMed ID: 25661282
[TBL] [Abstract][Full Text] [Related]
17. [Orexin: clinical and therapeutic implications].
Mediavilla C; Risco S
Rev Neurol; 2014 Feb; 58(3):117-24. PubMed ID: 24469938
[TBL] [Abstract][Full Text] [Related]
18. Recent trends in orexin research--2010 to 2015.
Boss C; Roch C
Bioorg Med Chem Lett; 2015 Aug; 25(15):2875-87. PubMed ID: 26045032
[TBL] [Abstract][Full Text] [Related]
19. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications.
Herring WJ; Roth T; Krystal AD; Michelson D
J Sleep Res; 2019 Apr; 28(2):e12782. PubMed ID: 30338596
[TBL] [Abstract][Full Text] [Related]
20. Suvorexant (Belsomra) for insomnia.
Med Lett Drugs Ther; 2015 Mar; 57(1463):29-31. PubMed ID: 25719996
[No Abstract] [Full Text] [Related]
[Next] [New Search]
